KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Construction in Progress (2016 - 2024)

Nektar Therapeutics (NKTR) has 15 years of Construction in Progress data on record, last reported at $245000.0 in Q4 2024.

  • For Q4 2024, Construction in Progress fell 66.85% year-over-year to $245000.0; the TTM value through Dec 2024 reached $245000.0, down 66.85%, while the annual FY2024 figure was $245000.0, 66.85% down from the prior year.
  • Construction in Progress reached $245000.0 in Q4 2024 per NKTR's latest filing, up from $138000.0 in the prior quarter.
  • Across five years, Construction in Progress topped out at $7.2 million in Q4 2021 and bottomed at $138000.0 in Q3 2024.
  • Average Construction in Progress over 5 years is $1.8 million, with a median of $731500.0 recorded in 2023.
  • The widest YoY moves for Construction in Progress: up 57.05% in 2024, down 71.72% in 2024.
  • A 5-year view of Construction in Progress shows it stood at $4.7 million in 2020, then soared by 52.4% to $7.2 million in 2021, then tumbled by 64.68% to $2.5 million in 2022, then plummeted by 70.79% to $739000.0 in 2023, then plummeted by 66.85% to $245000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Construction in Progress were $245000.0 in Q4 2024, $138000.0 in Q3 2024, and $724000.0 in Q2 2024.